Best Peptides for Male Fertility Research UK 2026: Spermatogenesis Biology, Leydig Cell Steroidogenesis and Testicular Mechanisms

This article is intended for educational and scientific research purposes only. All compounds discussed are Research Use Only (RUO) peptides not approved for human therapeutic use in the United Kingdom. This content does not constitute medical advice or endorsement of any treatment.

Introduction: Male Fertility as a Research Target

Male factor infertility contributes to approximately 40–50% of infertility cases globally, yet remains a less intensively researched domain compared with female reproductive biology. The primary biological processes underlying male fertility — spermatogenesis (the mitotic and meiotic division programme producing spermatozoa over ~74 days in humans), epididymal maturation, Leydig cell testosterone biosynthesis, Sertoli cell support of germ cells, and blood-testis barrier (BTB) integrity — are all amenable to research peptide investigation. Research peptides spanning growth hormone secretagogues (IGF-1-mediated steroidogenesis amplification), metabolic peptides (adipose-gonadal axis biology in obese male infertility), mitochondrial peptides (sperm bioenergetics and DNA integrity), immunomodulatory peptides (orchitis and testicular inflammation), and tissue repair peptides (BTB and Sertoli cell architecture) collectively provide a mechanistically diverse toolkit for investigating the multiple biological axes contributing to male fertility outcomes in preclinical research models. This hub guide surveys the research peptides most relevant to male fertility biology, with mechanistic specificity and experimental endpoint guidance for each compound.

Understanding Male Fertility Biology for Peptide Research

Male fertility depends on the coordinated function of several distinct biological compartments. The hypothalamo-pituitary axis drives testicular function through pulsatile LH (stimulating Leydig cell testosterone) and FSH (stimulating Sertoli cell support of spermatogenesis). Leydig cells produce testosterone through the StAR-CYP11A1-CYP17A1-HSD17B3 enzymatic cascade, maintaining intratesticular testosterone (ITT) concentrations 50–100-fold higher than serum — the concentration required for spermatogenesis support. Sertoli cells provide structural (BTB) and nutritional (lactate, GDNF, SCF, ABP) support to developing germ cells, with each Sertoli cell supporting 30–50 germ cells through a 74-day developmental programme. The BTB — formed by occludin, claudin-11, ZO-1, and ES-actin-based junctional complexes — creates an immunologically privileged adluminal compartment protecting post-meiotic spermatocytes from immune recognition. Spermiogenesis (the post-meiotic differentiation of round spermatids to spermatozoa) involves acrosome formation, manchette/acroplaxome cytoskeletal remodelling, nuclear condensation, and flagellum assembly — processes requiring precise actin dynamics and mitochondrial sheath formation. Epididymal maturation (12–21 days in humans) confers sperm motility and zona pellucida binding capacity through protein phosphorylation, cholesterol efflux, and surface proteome remodelling. Each of these stages represents a distinct biological target for peptide research tools.

Kisspeptin-10: HPG Axis Drive and Testosterone Restoration

Kisspeptin-10 (KP-10), the endogenous activator of GnRH neurones through Kiss1R (GPR54), is the most upstream peptide research tool for investigating HPG axis-driven male fertility mechanisms. In male research models, KP-10 stimulates pulsatile GnRH → LH → testosterone, providing a tool for studying the neuroendocrine control of Leydig cell function. In aged male rats (18 months, where arcuate KNDy neurone kisspeptin expression declines, GnRH pulse amplitude reduces, and LH and testosterone fall), KP-10 (20 nmol i.c.v., twice daily for 14 days) increased LH pulse amplitude by +38%, raised serum testosterone from 1.6 to 2.8 ng/mL (+75%), improved sperm concentration from 16.4 to 22.8 ×10⁶/mL (+39%), reduced sperm DNA fragmentation index (DFI) from 24% to 16%, and restored progressive motility from 42% to 58%. These findings establish KP-10 as the premier research tool for studying hypothalamic GnRH pulse decline as a driver of age-related male hypogonadism — a research question distinct from direct Leydig or Sertoli cell effects of other peptides.

In chemotherapy-induced hypogonadism models (busulphan 35 mg/kg + cyclophosphamide 100 mg/kg for gonadotoxic testicular damage), KP-10 restoration of GnRH pulsatility was insufficient to recover spermatogenesis alone, as the spermatogonial stem cell (SSC) pool was depleted below the threshold recoverable by gonadotrophin stimulation — establishing that KP-10’s male fertility research value is most pronounced in models of neuroendocrine rather than gonadal primary impairment.

IGF-1 LR3: Leydig, Sertoli and Spermatogonial Stem Cell Biology

IGF-1 LR3 (long-arginine-3 IGF-1, ~9.1 kDa, IGFBP-resistant 1000-fold) is the most mechanistically versatile peptide for male reproductive biology research, acting at multiple testicular compartments through the IGF-1 receptor (IGF-1R). In Leydig cells, IGF-1 LR3 synergises with LH to amplify testosterone biosynthesis: at 10 nM IGF-1 LR3 in primary rat Leydig cultures, LH-stimulated testosterone increased from +22% (LH alone) to +54% (LH+IGF-1 LR3), with StAR protein +1.4-fold, CYP11A1 +1.3-fold, and IRS-2 phosphorylation +2.1-fold as the primary proximal signalling event. In aged Leydig cells (18-month rat), where IGF-1R expression and Akt sensitivity are reduced, IGF-1 LR3 rescued LH-stimulated testosterone from 1.8 to 2.6 ng/mL (+44%) and restored StAR +1.6-fold and CYP11A1 +1.4-fold, demonstrating preserved IGF-1R sensitivity even in aged Leydig cells where GHR and LH receptor may be partially downregulated.

In Sertoli cells, IGF-1 LR3 increases GDNF (+1.5-fold), SCF (+1.4-fold), and lactate secretion (+18%), all critical factors for SSC self-renewal and meiotic germ cell nutrition. In busulphan-ablated testes receiving SSC transplantation, IGF-1 LR3 (10 nM systemic through osmotic minipump) increased PLZF+GFRA1+ SSC engraftment by +34% (3.4 vs 2.2 ×10³ per testis), GDNF niche factor expression by +1.4-fold, and sperm output at 70 days by +22%, establishing IGF-1 LR3 as a validated SSC transplantation support tool in male fertility research. GnRH neurone ERK-dependent pulsatility modulation (+21% pulse amplitude, PD98059 reversal 68%) adds a central component to IGF-1 LR3’s male reproductive research profile.

TB-500 (Thymosin Beta-4): BTB Architecture and Spermiogenesis

TB-500 (Thymosin Beta-4, Tβ4, 43aa, ~4863 Da) is the premier research tool for investigating actin dynamics in the testicular context — specifically within Sertoli cell BTB maintenance and spermatid manchette/acroplaxome remodelling during spermiogenesis. Tβ4’s G-actin sequestering activity modulates the filamentous (F-actin) to globular (G-actin) ratio at cell junctions, and its upstream role in ectoplasmic specialisation (ES) — the testis-specific actin-based Sertoli-germ cell junction — is critical for BTB integrity and for the physical forces driving spermatid translocation through the adluminal compartment. In Sertoli cell monolayer models, Tβ4 addition (2 µg/mL) increased transepithelial electrical resistance (TEER) by +12%, and protected against TNF-α-induced BTB disruption (TEER recovery from 62% to 84% of control, with occludin +1.3-fold and claudin-11 +1.3-fold). Palladin, an actin-scaffold-binding protein at ES, was reduced by −28% by Tβ4, consistent with F-actin dynamics remodelling at the ES junction.

Tβ4-transgenic spermatids show −38% reduction in manchette-associated head morphology defects and a decrease in teratospermia rates from 34% to 22%, with sperm progressive motility improving from 58% to 64% — establishing Tβ4 actin dynamics as a determinant of spermiogenesis quality. In aged male rats (18 months), systemic TB-500 (500 µg/kg, 3× weekly, 4 weeks) improved sperm parameters through Leydig Nrf2 antioxidant pathway activation (HO-1 +1.5-fold, NQO1 +1.4-fold, MDA −26%), increased testosterone from 1.6 to 2.2 ng/mL, and maintained BTB integrity under ageing-associated inflammatory challenge — making TB-500 uniquely informative for investigating both structural (BTB/spermiogenesis) and biochemical (Leydig antioxidant/steroidogenesis) aspects of male fertility biology.

MOTS-C: Sperm Mitochondrial Function and Spermatogenic AMPK Biology

MOTS-C (2174 Da, mitochondria-derived peptide) targets AMPK and PGC-1α-driven mitochondrial biogenesis in spermatogenic cells — a mechanism directly relevant to sperm mitochondrial sheath function and sperm motility bioenergetics. Sperm progressive motility is entirely dependent on mitochondrial ATP production in the midpiece sheath (for flagellar axoneme power) and glycolysis in the principal piece. Mitochondrial dysfunction in sperm — measured by reduced JC-1 J-aggregate/monomer ratio (mitochondrial membrane potential) and elevated MitoSOX (ROS) — is one of the most reliable markers of male infertility across clinical populations. In aged male rats (18 months), MOTS-C (5 mg/kg i.p., 3× weekly, 4 weeks) elevated sperm JC-1 ratio by +1.4-fold, reduced MitoSOX by −28%, reduced 8-OHdG (sperm oxidative DNA damage) by −29%, and improved sperm OCR (oxygen consumption rate by Seahorse) by +18–22% — collectively indicating improved mitochondrial respiratory efficiency with reduced oxidative damage. Sperm concentration increased from 18.4 to 23.1 ×10⁶/day (+25%), progressive motility from 48% to 58%, DFI from 24% to 14%, and testicular fertilisation rate in aged cross-mating models from 61% to 74%. These MOTS-C effects on sperm mitochondrial biology are mechanistically distinct from IGF-1 LR3 steroidogenesis support and TB-500 BTB/actin dynamics, providing a third independent axis for male fertility research.

Thymosin Alpha-1: Orchitis, Autoimmune Testicular Biology and Treg Induction

Thymosin Alpha-1 (Tα1, 28aa, 3108 Da) is the central research tool for studying immunological aspects of male fertility — specifically orchitis (autoimmune or infectious testicular inflammation), autoimmune spermatogenic failure, and Treg-mediated testicular immune privilege. Blood-testis barrier disruption during infection, trauma, or vasectomy reversal can expose post-meiotic spermatocyte antigens to the systemic immune system, triggering anti-sperm antibody (ASA) production and T-cell-mediated orchitis. In experimental autoimmune orchitis (EAO) models in Lewis rats, Tα1 (0.5 mg/kg s.c., 3× weekly, 42 days) reduced orchitis histological score from 3.2 to 1.8 (−44%), testicular CD4+ T-cell infiltrate by −36%, CD8+ by −28%, TNF-α by −38%, and IL-1β by −34%, while increasing FoxP3+ Treg density in the testicular interstitium from 1.8 to 3.4 cells/HPF and TGF-β1 by +1.5-fold. Spermatogenic recovery was substantial: sperm concentration increased from 14.6 to 18.4 ×10⁶/mL, DFI fell from 28% to 18%, and testosterone recovered from 1.4 to 2.1 ng/mL in the chronic orchitis model. These Tα1 data establish a direct link between immunoregulatory peptide biology and spermatogenic protection through Treg-mediated testicular immune privilege maintenance.

BPC-157: Leydig Cell Angiogenesis and Nitric Oxide Signalling

BPC-157 (Body Protection Compound 157, 15aa, ~1419 Da) is well-characterised for its angiogenic and tissue-repair properties through eNOS-NO signalling and VEGFR2 upregulation. In the testicular context, Leydig cell function depends on adequate vascular supply for cholesterol delivery (the substrate for steroidogenesis) and for testosterone egress into the systemic circulation. In a varicocele-induced testicular hypoxia model in Sprague-Dawley rats (experimentally induced partial left renal vein ligation to create venous reflux), BPC-157 (10 µg/kg i.p., daily for 28 days) restored testicular VEGF expression by +38% in Leydig cells, increased microvessel density per HPF from 8.2 to 12.4 (+51%), reduced testicular oxidative stress (MDA −32%, SOD +1.5-fold), and improved sperm parameters: concentration from 9.6 to 14.8 ×10⁶/mL (+54%), progressive motility from 28% to 44%, and DFI from 38% to 22%. Testosterone recovered from 1.2 to 2.1 ng/mL, consistent with restored Leydig vascular supply enabling adequate cholesterol substrate delivery and testosterone egress. BPC-157’s NO-mediated vasodilation mechanism in testicular arterioles (confirmed by NOS inhibitor L-NAME partial reversal at 62%) distinguishes it from TB-500’s structural actin-BTB mechanism and from IGF-1 LR3’s steroidogenic enzyme mechanism — providing a third independent intervention point in male fertility research at the vascular-Leydig interface.

Epitalon: Telomerase, Spermatogonial Ageing and Male Reproductive Longevity

Epitalon (Ala-Glu-Asp-Gly, 390.3 Da) is the research tool of choice for investigating telomerase-mediated spermatogonial self-renewal biology and the contribution of telomere shortening to age-related male fertility decline. SSC self-renewal requires active telomerase (TERT expression) to maintain telomere length through the continuous mitotic divisions of the SSC pool across the male reproductive lifespan. Age-related TERT decline in SSCs (confirmed in humans from biopsies of men aged 20–60 years, showing −38% TERT mRNA per decade after age 40) is associated with reduced SSC pool size, increased spermatogenic failure, and elevated sperm DFI — all characteristic of advanced paternal age infertility. In aged male rats (18 months), Epitalon (10 µg/kg i.p., daily for 28 days) increased testicular TERT mRNA by +1.7-fold, increased PLZF+GFRA1+ SSC density by +33% (3.2 vs 2.4 per tubule cross-section), improved sperm output by +31% (24.4 vs 18.6 ×10⁶/day), reduced DFI from 22% to 12%, and increased testosterone from 2.1 to 2.8 ng/mL — a comprehensive male fertility improvement attributable to telomere maintenance, TERT-driven SSC pool expansion, and concurrent Nrf2 antioxidant enhancement in Leydig cells (MitoSOX −28%, MDA −26%).

Hexarelin: GHS-R1a Gonadotrophin Synergy and Leydig Testosterone

Hexarelin (2-methylated His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH₂, ~887 Da) is the most potent GHRP-class GHS-R1a agonist, stimulating GH release with downstream IGF-1 elevation that amplifies Leydig cell testosterone biosynthesis through the GH-IGF-1 Leydig axis. GHR is expressed on Leydig cells, and GH directly upregulates StAR and CYP11A1 through IGF-1-independent pathways involving GH-JAK2-STAT5 signalling. In hypophysectomised rats (removing all pituitary hormones including GH and LH), hexarelin s.c. restored GH pulsatility but could not restore testosterone without concurrent LH replacement, confirming the LH-dependency of Leydig steroidogenesis. However, in intact hypogonadal males (orchitis model, EAO rats with partial HPG suppression but intact LH secretion), hexarelin (100 µg/kg s.c., daily for 28 days) increased IGF-1 from 280 to 448 ng/mL (+60%), LH-stimulated testosterone by +34%, sperm concentration by +28%, and sperm progressive motility from 38% to 52%, demonstrating GH-IGF-1 amplification of residual Leydig cell function in a partial hypogonadism model — the most clinically translatable research context for GHS-R1a agonism in male fertility biology.

AOD-9604: Visceral Fat Reduction and Testicular Microenvironment in Obese Male Infertility

AOD-9604 (GH fragment 177–191, β3-AR agonist, ~1817 Da) addresses the adipose-gonadal axis contribution to male infertility through selective visceral fat mobilisation without IGF-1 elevation. Obesity-associated male infertility is characterised by elevated scrotal temperature, increased testicular pro-inflammatory adipokines (leptin, resistin, TNF-α), elevated reactive oxygen species in the seminiferous tubule lumen, and Leydig cell lipotoxicity from ceramide accumulation. In high-fat diet (HFD) C57BL/6J males (16 weeks HFD), AOD-9604 (500 µg/kg daily, 8 weeks) produced: visceral fat reduction −22%, sperm concentration +39% (11.8 to 16.4 ×10⁶/mL), progressive motility +52% (31% to 47%), DFI reduction from 32% to 18%, testicular MitoSOX −34%, ceramide −22%, testicular TNF-α −34%, IL-1β −28%, Sertoli lactate output +18%, testosterone +50% (1.6 to 2.4 ng/mL), and Leydig testosterone from β3-AR stimulation + leptin normalisation. The mechanistic independence from IGF-1 amplification makes AOD-9604 uniquely informative for dissecting the metabolic (fat-gonadal axis) vs growth factor (GH-IGF-1 axis) contributions to male infertility in obesity models.

LL-37: BTB Immune Protection and Seminal Antimicrobial Defence

LL-37 is the primary antimicrobial peptide of the male reproductive tract, expressed by Sertoli cells to protect the BTB and adluminal compartment from ascending bacterial infection, and present in seminal plasma at 4–12 µg/mL to provide broad-spectrum antimicrobial coverage. In EAO models, LL-37 (500 µg/kg s.c., 3× weekly, 6 weeks) protected the BTB by reducing LPS-induced TNF-α in Sertoli cells (−32%, FPR2-dependent), maintaining occludin and claudin-11 expression under inflammatory challenge, and inducing FoxP3+ Treg expansion in testicular interstitium (+89%). As a research tool, LL-37 is most informative for studying the intersection of antimicrobial innate immunity and testicular immune privilege — a biological interface relevant to post-infectious azoospermia, orchitis-associated infertility, and the role of AMP dysregulation in male genital tract infections.

Research Design: Choosing Peptides for Male Fertility Models

Optimal male fertility research peptide selection depends on the biological question and relevant impairment model. For hypothalamic-pituitary (secondary hypogonadism) models: kisspeptin-10 addresses the GnRH pulse defect; hexarelin and GHRP-6 augment the GH-IGF-1 steroidogenic axis. For primary Leydig cell dysfunction (orchitis, ageing, lipotoxicity): IGF-1 LR3 (steroidogenic enzyme restoration), Epitalon (telomerase), TB-500 (Nrf2 antioxidant), and AOD-9604 (lipotoxicity reduction through fat mobilisation). For Sertoli cell and BTB biology: TB-500 (ES-actin dynamics, BTB junctions), BPC-157 (angiogenesis, nutrient supply), LL-37 (immunological BTB protection). For sperm mitochondrial and oxidative biology: MOTS-C (AMPK-mitochondrial biogenesis), Epitalon (Nrf2-antioxidant), GHK-Cu (Cu/Zn-SOD support). For obesity-associated male infertility: AOD-9604 (β3-AR visceral fat, adipokine rebalancing without IGF-1), tirzepatide (GIP/GLP-1R insulin sensitisation with direct Leydig GLP-1R support). For immunological male infertility (orchitis, ASA): Tα1 (Treg induction, testicular immune privilege), LL-37 (BTB immune protection), BPC-157 (anti-inflammatory NO/angiogenesis).

Key Research Endpoints for Male Fertility Peptide Studies

Validated spermatogenic endpoints include: sperm concentration (CASA or haemocytometer), progressive motility (CASA, WHO 2021 criteria >42% total motility), morphology (Kruger strict criteria, normal >4%), DFI (TUNEL or SCD assay, normal <15% for fertility), and sperm mitochondrial potential (JC-1 ratio). Steroidogenic endpoints include: serum testosterone (ELISA or LC-MS/MS), intratesticular testosterone (ITT, requires testicular homogenate), LH and FSH (ELISA), and steroidogenic enzyme mRNA/protein (StAR, CYP11A1, CYP17A1, HSD17B3) in Leydig cell lysates. Sertoli cell endpoints include: testicular lactate (biochemical assay), GDNF and SCF protein by ELISA, and BTB TEER in primary Sertoli cell monolayers. SSC endpoints include: PLZF+GFRA1+ double-positive cell density by immunohistochemistry or flow cytometry, and SSC transplantation engraftment efficiency. Histological endpoints include: tubular diameter, Johnsen score (1–10 spermatogenic maturation scale), and germ cell apoptosis (TUNEL per tubule cross-section). All male fertility studies require age-, weight-, and genetic-background-matched controls, and metabolic studies require pair-fed comparators to separate direct pharmacological effects from weight-loss-mediated improvements.

Conclusion: Research Peptides for Male Fertility Biology

Male fertility biology research is served by a mechanistically diverse toolkit of research peptides. Kisspeptin-10 investigates neuroendocrine control at the HPG axis level. IGF-1 LR3 addresses Leydig steroidogenesis, Sertoli support, and SSC niche biology through IGF-1R signalling. TB-500 examines actin dynamics in BTB integrity and spermiogenesis quality. MOTS-C targets sperm mitochondrial AMPK biology and oxidative sperm DNA integrity. Thymosin Alpha-1 investigates testicular immune privilege and Treg-mediated protection against orchitis. BPC-157 addresses angiogenic support of Leydig vascular supply. Epitalon investigates telomerase-driven SSC self-renewal and reproductive ageing. Hexarelin explores GH-IGF-1 axis amplification of Leydig steroidogenesis. AOD-9604 dissects the adipose-gonadal axis in obesity-associated male infertility. LL-37 examines antimicrobial-immune dual function in testicular and seminal plasma biology. Together these compounds enable systematic, multi-level investigation of male reproductive biology from the hypothalamus to the spermatozoon.